Cagrilintide | CAS 1415456-99-3 | Dual Amylin/Calcitonin Receptor Agonist (Research Use Only) | Knowlux

Product Description

Cagrilintide, CAS 1415456-99-3, is a synthetic long-acting amylin analogue supplied by Knowlux for laboratory research use. It is a 38-amino-acid cyclic peptide containing a disulfide bridge between Cys2 and Cys7, with a C-terminal proline amide and a lipidated side chain that extends its half-life to support once-weekly dosing. The molecular formula is C194H312N54O59S2 and the molecular weight is 4409.01 g/mol. Each lot is released with a lot-specific COA, MSDS and full analytical traceability.

Product Parameters

Product Details

1. Overview

Cagrilintide is a long-acting acylated analogue of human amylin, a hormone co-secreted with insulin by pancreatic beta cells in response to food intake. It was engineered to resist rapid degradation while retaining affinity for amylin receptors, and its extended half-life supports once-weekly subcutaneous administration in clinical development settings. Cagrilintide is under investigation for obesity and type 2 diabetes, both as a monotherapy and in fixed-dose combination with semaglutide (CagriSema). As of the current research literature, it remains an investigational molecule and is not approved as a therapeutic product in any jurisdiction.

2. Mechanism of Action

Cagrilintide functions as a dual agonist at amylin receptors (AMYRs) and the calcitonin receptor (CTR), a pharmacological class referred to as DACRA (dual amylin and calcitonin receptor agonist). Cryo-EM structural studies indicate that cagrilintide adopts a bypass binding mode at both AMY1R and CTR, distinct from DACRAs that rely primarily on N-terminal lipid modification for half-life extension. Key molecular features include the F23 residue anchoring the peptide at the receptor transmembrane bundle, an E14-R17 intramolecular salt bridge that stabilizes the helical conformation, and the C-terminal P37 interaction with the receptor extracellular domain. Functional analyses confirm non-selective activation of Gs signalling through both receptor pathways. The downstream effect is reduced appetite, slowed gastric emptying, and enhanced satiety, consistent with amylin biology.

3. Quality Control

Full COA, MSDS, and lot-specific chromatograms are issued with each shipment. Custom specifications and third-party inspection can be arranged.

4. Applications

• Reference standard and impurity studies for amylin/calcitonin receptor agonist analytical methods

• AMYR and CTR binding and functional assay development

• Formulation development for long-acting injectable peptides

• Metabolic disease model research, including appetite regulation and glucose homeostasis studies

• LC-MS, immunoassay and bioassay calibrators

5. Packaging, Storage & Shipping

Lyophilized powder: amber glass vial under nitrogen headspace, sealed with butyl stopper and aluminium crimp. Secondary packing: tamper-evident, light-protected carton with desiccant. Cold-chain shipping with validated gel packs and temperature logger; dry ice for -20 C shipments. COA, MSDS, packing list and certificate of origin issued with each shipment.

6. Documentation Support

Per lot: COA, MSDS, certificate of origin, residual solvent statement, counter-ion specification. Regulatory packages (specification summaries, audit support) available on a project basis.

About Knowlux

Knowlux Biotechnology is a GMP-oriented manufacturer and supplier of peptides, APIs and fine-chemical research compounds, operating from Hubei, China. We serve research groups, CDMOs and distributors in more than 40 countries, and support contract synthesis, custom packaging and technical documentation requests.

Compliance Statement

This product is supplied for laboratory research use only. It is not for human or animal administration, not for diagnostic or therapeutic use, not for retail sale, and not for personal use. Cagrilintide is an investigational molecule and is not approved as a medicinal product in any jurisdiction. Under EU regulations, this peptide is not a notified novel food and cannot serve as a supplement ingredient; consignments presented for oral consumer use are non-compliant. In the United States, it cannot lawfully be compounded under section 503A because it is neither a component of an approved drug, nor covered by a USP monograph, nor listed as a permitted bulk substance. Research context statements are for scientific reference only and do not constitute medical advice, promotional claims, or dosing guidance.